Form 4: NewAmsterdam Pharma Director Louis G. Lange Reports Beneficial Ownership Changes

Director Louis G. Lange reports changes in beneficial ownership of NewAmsterdam Pharma Co N.V. ordinary shares and Restricted Stock Units (RSUs) due to vesting.

Summary

• On May 1, 2025, Louis G. Lange, a director of NewAmsterdam Pharma Co N.V., reported changes in his beneficial ownership of the company's securities.
• The changes involve the vesting of 69 ordinary shares and 69 Restricted Stock Units (RSUs).
• Following the transaction, Lange directly owns 68 RSUs and indirectly owns 28,118 ordinary shares through the LGLange III Trust DTD10.
• The RSUs were granted on March 26, 2025, as earnout RSUs related to a business combination agreement from July 25, 2022, contingent on achieving a clinical development milestone.
• The right to receive the earnout RSUs became fixed and irrevocable on the Closing Date of the business combination agreement.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive as it reflects the expected vesting of RSUs based on a prior agreement and continued service. It doesn't indicate any significant positive or negative developments.

Positives

• The vesting of RSUs indicates the achievement of certain milestones related to the business combination agreement.

Future Outlook

The remaining 68 RSUs will vest on June 1, 2025, subject to the Reporting Person's continued service with the issuer.

Industry Context

This filing is a routine disclosure related to changes in beneficial ownership by a company insider, which is a common occurrence in publicly traded companies. It provides transparency to investors regarding the holdings of key individuals within the company.

Stakeholder Impact

• The vesting of RSUs aligns the director's interests with those of the shareholders, incentivizing continued service and performance.

Key Dates

Keywords

beneficial ownership, Form 4, NewAmsterdam Pharma, RSU, director, Lange, vesting, shares